Parkinson's Disease Market Global Clinical Trials Review, H2, 2016

PUNE, INDIA, November 17, 2016 /EINPresswire.com/ -- This report provides top line data relating to the clinical trials on Parkinson's disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/735120-parkinson-s-disease-global-clinical-trials-review-h2-2016

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Parkinson's Disease to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Parkinson's Disease Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Parkinson's Disease 30
Sep 29, 2016: NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications 30
Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease 30
Sep 20, 2016: Adamas Announces Results of EASE LID 3, a Pivotal Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Parkinson Disease Patients at the 4th World Parkinson Congress 31
Sep 19, 2016: Parkinsons disease: Prexton Therapeutics completes phase 1 clinical trial 32
Sep 19, 2016: NeuroDerm to Present ND0612L Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System 32
Sep 19, 2016: NeuroDerm to Present ND0612H Data at 4th World Parkinson Congress 33
Sep 12, 2016: Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 4th World Parkinson Congress 33

Access Report @ https://www.wiseguyreports.com/reports/735120-parkinson-s-disease-global-clinical-trials-review-h2-2016


Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Ruwin Mendez
Market Research Future
+1 (339) 368 6938
email us here